VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
Go back to VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder| (NASDAQ: VTGN) | Delayed: 0.25 +0.01 (4.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.24 | 52 Week High | $4.60 | |||
| Open | $0.24 | 52 Week Low | $2.81 | |||
| Day High | $0.27 | P/E | N/A | |||
| Day Low | $0.24 | EPS | $0.00 | |||
| Volume | 4,441,150 | |||||
